Stock Market Movers: Best and Worst Performers of 14 October 2026

Mavacamten showed sustained reduction in LVOT gradient in pediatric oHCM patients over 56 weeks, according to data presented at AHA 2026. The SCOUT-HCM trial, sponsored by Bristol-Myers Squibb, found significant improvements in efficacy endpoints with a favorable safety profile. Investigator Joseph Rossano discussed potential next steps for real-world studies. (BMY)

Lupus patients are enrolling in experimental CAR-T trials despite recent deaths in trials by Novartis (3) and Bristol Myers Squibb (1). Doctors note the potential benefits outweigh risks for severe lupus cases. Novartis and Bristol Myers have paused trials but plan to resume. CAR-T is also being tested for other autoimmune diseases, with about 150 trials underway. Cabaletta Bio's therapy shows promise with a traditional manufacturing process.

Bristol Myers Squibb's mavacamten (Camzyos) showed sustained benefits in adolescents with oHCM at 56 weeks, per SCOUT-HCM trial data. Patients maintained reduced LVOT obstruction, with no LVEF below 50%. The FDA approved mavacamten for pediatric oHCM in September 2026. The drug is available only through the Camzyos REMS Program, requiring echocardiographic monitoring and dose adjustments.

Bristol Myers Squibb presented 56-week data from the SCOUT-HCM trial, showing sustained benefits of mavacamten (Camzyos) in adolescents with obstructive hypertrophic cardiomyopathy (oHCM). The study found no new safety concerns, with mean Valsalva LVOT gradient reductions of -48.1 mm Hg. The FDA approved mavacamten for pediatric use in September 2026, making it the only FDA-approved therapy for oHCM in this population.

Phase 3 trials show elafibranor (Ipsen) and seladelpar (Gilead Sciences) effectively normalize ALP levels in PBC patients. Both drugs were approved in 2024 for inadequate UDCA response. Trials reported significant ALP reduction and normalization rates, with safety profiles similar to placebo.

Bristol-Myers Squibb (BMY) reported 56-week Phase 3 data for Camzyos in pediatric obstructive hypertrophic cardiomyopathy, showing sustained efficacy and consistent safety. The data supports BMY's growth portfolio strategy, with analysts watching for prescription trends and long-term safety updates. BMY has a $127.0b market cap and develops therapies across multiple disease areas.